Diagnostic accuracy and clinical utility of a simplified low cost method of counting CD4 cells with flow cytometry in Malawi: diagnostic accuracy study

Calman A MacLennan, Wellcome Trust research fellow and clinical lecturer in immunology,1 2 Michael K P Liu, postdoctoral immunologist,2 Sarah A White, biostatistician,1 Joep J G van Oosterhout, senior clinical lecturer in medicine,3 Felanji Simukonda, laboratory scientist,1 Joseph Bwanali, laboratory technician,1 Michael J Moore, laboratory manager,1 Eduard E Zijlstra, professor of medicine,2 Mark T Drayson, senior clinical lecturer in immunology,2 Malcolm E Molyneux, director1

ABSTRACT

Objectives To assess the diagnostic accuracy and clinical utility of a simplified low cost method for measuring absolute and percentage CD4 counts with flow cytometry.

Design A CD4 counting method (Blantyre count) using a CD4 and CD45 antibody combination with reduced blood and reagent volumes. Diagnostic accuracy was assessed by measuring agreement of the index test with two other assays (TruCount and FACSCount). Clinical utility was investigated by comparing CD4 counts with the new assay with WHO clinical staging in patients with HIV.

Setting Research laboratories and antiretroviral therapy clinic at a medical school and large government hospital in southern Malawi.

Participants Assay comparisons were performed on consecutive blood samples sent for CD4 counting from 129 patients with HIV. Comparison of CD4 count with staging was conducted on 253 consecutive new patients attending the antiretroviral therapy clinic.

Main outcome measures Limits of agreement with 95% confidence intervals between index test and reference standards.

Results The limits of agreement for Blantyre count and TruCount were excellent (cell count −48.9 to 27.0 × 10^9/l for absolute counts in the CD4 range <400 × 10^9/l and −2.42% to 2.37% for CD4 percentage). The assay was affordable with reagent costs per test of $0.44 (€0.22, £0.33) for both absolute count and CD4 percentage, and $0.11 for CD4 percentage alone. Of 193 patients with clinical stage I or II disease, who were ineligible for antiretroviral therapy by clinical staging criteria, 73 (38%) had CD4 counts <200 × 10^9/l. By contrast, 12 (20%) of 60 patients with stage III or IV disease had CD4 counts >350 × 10^9/l.

Conclusions This simplified method of counting CD4 cells with flow cytometry has good agreement with established commercial assays, is affordable for routine clinical use in Africa, and could improve clinical decision making in patients with HIV.

INTRODUCTION

In Malawi, a sub-Saharan African country with a population of 12 million, an estimated million people are infected with HIV.1 In 2004 the Ministry of Health embarked on an ambitious antiretroviral therapy programme. By the end of March 2007, 95 674 patients had started free antiretroviral therapy in public sector clinics,2 largely on the basis of a clinical diagnosis of WHO stage III or stage IV HIV/AIDS.3 Clinical events, however, do not fully predict immunological status.4 When clinical criteria alone are used, some patients with stage I and stage II disease and severe immune suppression will not receive the treatment they need, while others with stage III and IV disease may still have high CD4 T cell counts and the start of antiretroviral therapy might be delayed.5

CD4 counting could therefore improve appropriate allocation of antiretroviral therapy.3 Despite initiatives by the Clinton Foundation and others to reduce the price of the necessary reagents for developing nations to $3-6 (£1.5-3.0; €2.2-4.4) per test,7 this cost is still high for Africa.3 CD4 counting with flow cytometry is perceived by many to be too complex for use in Africa. For these reasons, CD4 counts are not routinely performed in Malawi.9 WHO guidelines state that where CD4 counting is available, adults and children over 5 years with HIV should start antiretroviral therapy as soon as their CD4 counts drop below 200 × 10^9/l, regardless of clinical staging.7 In children under 5 years, CD4 percentage of total lymphocyte count (CD4 percentage) varies less than absolute counts with age10 and so the percentage value is recommended to help decide on initiation of antiretroviral therapy.11

There are two main approaches for making CD4 counting more widely available in Africa: firstly, to reduce the cost of and simplify flow cytometric CD4 counting, and, secondly, to develop alternative counting methods. Flow cytometry, however, is the ideal method and has high accuracy.3–5 High throughput is possible as about 250 samples a day can be processed.8 Effective external quality assurance schemes are
Over recent years several technological developments have shown that flow cytometric CD4 counting could be more straightforward. “Primary CD4 gating” uses just one antibody against CD4 and side scattered light to discriminate between lymphocytes and monocytes.20,21 Gating of lymphocytes by using CD45 expression and side scattered light is more accurate and reproducible than using light scatter characteristics alone.22,23 Recently, CD45 has been used to gate all leucocytes on dual platforms, using a flow cytometer for CD4 percentage and a haematological analyser for absolute leucocyte counts.24 This “panleucogating” strategy has been modified for single platforms (flow cytometer alone) but remains primarily focused on total leucocytes rather than on lymphocytes.

We investigated whether these technologies could be miniaturised to reduce costs and applied them to the FACSCalibur flow cytometer. We developed a single platform method (the Blantyre count) that could be performed with reduced reagent costs and could accurately determine both absolute and percentage CD4 with increased simplicity compared with existing flow cytometric methods. We compared our method with the existing TruCount and FACSCount CD4 counting assays for diagnostic accuracy and assessed the potential impact on clinical decision making.

METHODS
Setting
The study was conducted at the Malawi-Liverpool-Wellcome Trust Research Programme and Queen Elizabeth Central Hospital in Blantyre, the largest city in the southern region of Malawi. The estimated prevalence of HIV infection among adults in Blantyre district is 22%.25 All participants gave informed consent for CD4 counting.

Instrumentation
We used a FACSCalibur flow cytometer, a FACSCount instrument (both Becton Dickinson, CA, USA), and Hamx haematological analyser (Beckman Coulter, CA, USA). We analysed flow cytometric data with CellQuest and MultiSet software.

Reference standards (TruCount and FACSCount assays)
We used TruCount26 and FACSCount27 assays for CD4 counts using Multitest CD3/8/45/4 kits with TruCount tubes and FACSCount reagent kits (Becton Dickinson) according to the manufacturer’s instructions. TruCount assays use four antibodies, a complex subgating strategy, and tubes containing pre-pipetted beads. We chose TruCount as the reference standard because it is a commercial CD4 counting method that was developed to be used on the same instrument as the index test (Becton Dickinson FACSCalibur flow cytometer) and generates both absolute and percentage CD4. We used FACSCount as a second reference standard because it is one of the most widely used CD4 counting technologies in Africa. Both TruCount and FACSCount generate CD4 counts on a single platform, although FACSCount

![Diagram](image1.png)

**Fig 1** Gating strategies for determining absolute and percentage CD4 counts from flow cytometric data acquired with Blantyre count. R1=CD4 positive T lymphocytes, R2=CytoCount fluorescent microbeads, R3=total lymphocytes, M=monocytes, N=neutrophils, L=CD4 negative lymphocytes. Plots are for data acquired from same blood sample with CD4 count=199×10⁹/l and CD4 percentage 17.6% with Blantyre count assay. Top: dot plot of side scattered light against CD4-PE (phycoerythrin). Absolute CD4 count=R1/R2)×[beads]/µl/2); bottom: contour plot of side scattered light against CD45-FITC (fluorescein isothiocyanate). CD4 percentage=(R1 (from top)/R3)×100 available in Africa with NEQAS (United Kingdom national external quality assessment scheme)13 and WHO CD4 REQAS/QASI (regional external quality assurance scheme/quality assessment and standardisation for immunological measures relevant to HIV/AIDS programme).14 Finally, flow cytometers can measure CD4 percentage as well as absolute counts. The main disadvantages are that flow cytometers are expensive and complex, reagent costs are high, and skilled laboratory staff are required.

Alternative counting methods include enzyme linked immunosorbent assays (ELISA),15 dried whole blood spots,16 lymphocyte rosetting,17 and magnetic beads.18 Such methods do not require complex equipment or the same level of staff training. The major disadvantage of such methods is poor ability to discriminate between CD4 T cells and monocytes, which also express CD4,19 low throughput, and poor ability to determine CD4 percentage. Reagent costs are similar to those of flow cytometric methods.8

[Reference](http://www.bmj.com/ on 17 June 2007 by guest. Protected by copyright.)
requires a lymphocyte count from a haematological analyser to generate CD4 percentage. Both assays are used by clinical laboratories throughout the world and have been validated by consistently high performance in external quality assurance schemes such as UK NEQAS\(^{15}\) over a period of years.

**Index test (Blantyre count assay)**

We used venous blood from healthy adults anticoagulated with EDTA to develop our assay. We used antihuman CD4 antibody conjugated with phycoerythrin (CD4-PE) and antihuman CD45 antibody conjugated with fluorescein isothiocyanate (CD45-FITC), FACS lysing solution (all Becton Dickinson), and CytoCount fluorescent microbeads (Dako, Denmark). Adjustable air-displacement pipettes (Pipetman; Gilson, France) were used for all pipetting steps. The same pipette was used for reverse pipetting of blood and counting beads. CD4 T cell counts and total lymphocyte populations were determined by using staining for CD4 and CD45 with no attempt to gate total leucocytes or total T cells. We mixed 20 \(\mu\)l whole blood with 0.5 \(\mu\)l CD4-PE and 0.5 \(\mu\)l CD45-FITC antibodies and incubated samples for 15 minutes in the dark at room temperature. Red cells were lysed with 180 \(\mu\)l of 1× FACS lysing solution and incubated for a further 10 minutes. We added 10 \(\mu\)l of CytoCount beads by reverse pipetting before we ran samples through the cytometer. We used reverse pipetting for pipetting blood and counting beads as precise volumes are critical and this method is more accurate than conventional pipetting.\(^{12}\) Pipette calibration and pipetting accuracy were assessed by dispensing 10 \(\mu\)l and 20 \(\mu\)l aliquots of water on to a scientific balance.

Bead events, 2000 per sample over about 60 seconds, were acquired by using a live gate with acquisition threshold set on the FL1 (FITC) channel. Analysis was performed with a CD4-PE against side scatter dot plot with manual gating of the CD4 T cell population (R1) and counting beads (R2) (fig 1 top) and a separate side scatter against CD45-FITC contour plot for manual gating of the total lymphocyte population (R3) (fig 1 bottom).

We calculated absolute CD4 counts (\(\times 10^9/\text{l}\)) with the formula: \(\text{CD4 T cell events (R1)/bead events (R2)} \times \left(\frac{\text{bead solution} \times \text{beads/\mu l}}{2}\right)\).

We calculated CD4 percentage with the formula: \(\frac{\text{CD4 T cell events (R1)/lymphocyte events (R3)}}{100}\).

We assessed repeatability of our assay by performing five repeats of the assay on four blood samples and examined stability of results with time by leaving a blood sample in the laboratory at room temperature and performing five repeats of the assay daily on the sample over five days.

**Modified Blantyre count assays**

We modified our assay to reduce costs further when only an absolute or percentage CD4 is required. The absolute CD4 count alone variant used CD4-PE antibody plus beads but without CD45-FITC antibody (Blantyre count (absolute)). The variant giving the CD4 percentage alone used CD4 and CD45 antibodies without counting beads (Blantyre count (percentage)).

**CD4 counting comparison studies**

In the main CD4 counting comparison study we included consecutive blood samples from patients with HIV sent to our laboratory for full blood count and CD4 count determination from 27 January to 17 February and from 18 April to 9 May 2006 (\(n=134\)). We measured CD4 and CD4 percentage for each sample using Blantyre count, Blantyre count (absolute), TruCount, and FACSCount assays.

We carried out a subsequent smaller study on consecutive blood samples from patients with HIV sent to the laboratory in June 2006 to compare CD4 percentages generated by Blantyre count and Blantyre count (percentage) assays (\(n=28\)). Samples were not used if they exhibited clots, were sent from outside Queen Elizabeth Central Hospital, or were received after the day of blood collection or if insufficient blood was available to complete all tests. There were no other selection criteria. Blood samples were analysed on the day that they were taken unless they were received after 4 pm in which case they were processed the next morning. Data collection was planned before the index tests and reference standards were performed. All blood samples from all participants meeting the inclusion criteria underwent the index and reference standard tests. No adverse events occurred from performing these tests.

| Table 1 | Reagent costs per assay with flow cytometry for counting CD4 cells. Costs calculated with prices available to us in $ for all reagents |
| CD4 assay | CD4-PE antibody | CD45-FITC antibody | Red cell lysising solution | Fluorescent beads* | Kit | Total |
| Blantyre count: | | | | | | |
| Absolute and percentage | 0.056 | 0.042 | 0.014 | 0.329 | 0.64 |
| Absolute | 0.056 | — | 0.014 | 0.329 | 0.40 |
| Percentage | 0.056 | 0.042 | 0.014 | — | — |
| TruCount (Multitest) (absolute and percentage) | — | — | 0.036† | — | 5.00 | 5.04 |
| FACSCount (absolute) | — | — | — | — | 6.00 | 6.00 |

CD4-PE=phycoerythrin conjugated antihuman CD4 antibody; CD45-FITC=fluorescein isothiocyanate conjugated antihuman CD45 antibody.

*Allowing for 12 \(\mu\)l assay with reverse pipetting.

†Not provided with kit; 450 \(\mu\)l of 1× lysis solution required/assay.
Two authors (FS and JB) performed and read the FACSCount assay and full blood count. Two other authors (MKPL and CAM), both of whom had previous experience of flow cytometry, performed and read TruCount and Blantyre count assays together within six hours of the FACSCount assay. We have subsequently trained local laboratory technicians over two to three days to perform the Blantyre count method. Manual gating of events acquired with Blantyre count was performed blind to other results. As the FACSCount does not give CD4 percentages, we calculated this from the FACSCount absolute CD4 count and total lymphocyte count from the haematological analyser using the formula (CD4 cells x10^9/l)/total lymphocyte count (cells x10^9/l) x 100. This procedure is prone to error because CD4 percentage is generated on a dual platform setting, which is inherently more variable than single platform operations. For absolute CD4 counts, we assessed agreement only for samples with a TruCount CD4 count below 400 x10^9/l as this is the relevant range for clinical decision making. For comparisons of CD4 percentage we used all samples.

Clinical utility study
We tested a further 253 EDTA anticoagulated venous blood samples from new patients attending the adult antiretroviral therapy clinic performed staging blind to CD4 count results.

External quality assurance
To determine the accuracy of Blantyre count, we enrolled the assay for external quality assurance with the NEQAS immune monitoring scheme. CD4 results were determined on six NEQAS stabilised blood samples from the UK between January and May 2006.

Statistical analysis
We examined agreement between each pair of methods using Stata 9 by estimating bias and limits of agreement (=bias plus or minus 1.96 x SD) with 95% confidence intervals as described by Bland and Altman. Repeatability was assessed with coefficients of variation obtained from five repeats of assays.

RESULTS
Refinement of Blantyre count
With 20, 10, 5, 2, and 1 µl of control blood per Blantyre count assay, coefficients of variation were 4.2%, 4.2%, 6.1%, 8.1%, and 10.7%, respectively, showing a progressive increase in coefficients of variation below 10 µl of blood. There was a decrease in mean absolute CD4 count as blood volume was reduced (712, 681, 645, 539, and 448 x10^9/l, respectively). CD4 percentages showed better overall repeatability (coefficients of variation 2.8% with 20 µl blood) and the coefficient
of variation did not noticeably increase until blood volume was reduced to 2 μl (4.8%). We used 20 μl blood for our assay as twice the lowest volume at which optimal assay repeatability was maintained.

We used a similar process to determine optimal counting bead volume. With 10 μl counting beads the coefficient of variation was 4.2%, and similarly with 5 μl beads (4.3%), but increased to 8.9% and 5.7% with 2 and 1 μl beads, respectively. Mean CD4 counts were not affected by bead volume. We used 10 μl counting beads for our assay. Finally, we titrated down the quantities of antibody per assay. Discrimination of CD4 T cell and total lymphocytes as discrete populations was still possible down to 0.25 μl of CD4-PE and 0.25 μl CD4-5-FITC. We chose 0.5 μl of each antibody for use in our assay. Using these quantities, the cost of reagents per assay were $0.44 ($0.22, $0.33) for both absolute and percentage counts, $0.40 for an absolute measure absolute and percentage CD4 cell counts and Blantyre count and TruCount Absolute CD4

*CD4 percentages with FACSCount calculated from absolute CD4 count by FACSCount and total lymphocyte count from haematological analyser.

Table 2 | Estimated bias and limits of agreement, with 95% confidence intervals for pairs of flow cytometric methods used to measure absolute and percentage CD4 cell counts

<table>
<thead>
<tr>
<th>Assay comparison</th>
<th>Bias (95% CI)</th>
<th>Limits of agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Lower limit (95% CI)</td>
</tr>
<tr>
<td>Absolute CD4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blantyre count and TruCount</td>
<td>−11.0 (−14.9 to −7.1)</td>
<td>−48.9 (−55.7 to −42.1)</td>
</tr>
<tr>
<td>FACSCount and TruCount</td>
<td>1.2 (−2.6 to 4.9)</td>
<td>−35.4 (−41.9 to −28.8)</td>
</tr>
<tr>
<td>Blantyre count and FACSCount</td>
<td>−12.1 (−16.6 to −7.7)</td>
<td>−54.8 (−62.4 to −47.1)</td>
</tr>
<tr>
<td>Blantyre count and Blantyre count (absolute)</td>
<td>−5.8 (−9.3 to −2.3)</td>
<td>−39.3 (−45.3 to −33.3)</td>
</tr>
<tr>
<td>CD4 percentage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blantyre count and TruCount</td>
<td>−0.03 (−0.24 to 0.19)</td>
<td>−2.42 (−2.78 to −2.05)</td>
</tr>
<tr>
<td>FACSCount* and TruCount</td>
<td>0.92 (0.32 to 1.52)</td>
<td>−5.83 (−6.87 to −4.79)</td>
</tr>
<tr>
<td>Blantyre count and FACSCount*</td>
<td>−0.94 (−1.53 to −0.35)</td>
<td>−7.56 (−8.57 to −6.54)</td>
</tr>
<tr>
<td>Blantyre count and Blantyre count (percentage)</td>
<td>0.01 (−0.26 to 0.28)</td>
<td>−1.35 (−1.82 to −0.88)</td>
</tr>
</tbody>
</table>

*CD4 percentages with FACSCount calculated from absolute CD4 count by FACSCount and total lymphocyte count from haematological analyser.
SD of the NEQAS value, with one result of six between 1 and 2 SD of this value for each test. Blantyre count values were on average 95% of the absolute NEQAS CD4 count and 97% of the CD4 percentage.

**Stability of aged samples**

CD4 T cell and lymphocyte populations could be clearly distinguished and gated over the five days of the stability study, with a blood sample with day 1 CD4 count of $4.87 \times 10^9$ l$^{-1}$ and CD4 percentage of 36.1%. Daily coefficients of variation for absolute counts remained below 6% and for CD4 percentage below 2.5%. The mean absolute CD4 count stayed within 10% and the CD4 percentage within 5% of the day 1 values.

**Clinical staging and CD4 counts for new patients attending antiretroviral therapy clinic**

Of the new patients attending the antiretroviral therapy clinic, 76% (193/253) were clinical stage I (n=77) or stage II (n=116), while 24% (60/253) had stage III (n=51) or stage IV (n=9) HIV/AIDS. The range of CD4 counts in each group was wide with a progressive fall in median CD4 counts from stage I ($286 \times 10^9$ l$^{-1}$) to stage IV groups ($110 \times 10^9$ l$^{-1}$). Twenty five (32%) patients with stage I disease and 48 (42%) with stage II disease had a CD4 count $<200 \times 10^9$ l$^{-1}$. Eleven (22%) patients with stage III and one (11%) patient with stage IV HIV/AIDS had a CD4 count $>350 \times 10^9$ l$^{-1}$ (table 3).

**DISCUSSION**

Within Malawi, we have developed an affordable accurate method of counting CD4 cells with flow cytometry by refining and miniaturising existing technology. Increasing affordability by reducing reagent costs is a critical step in making this available in countries with limited resources. Currently the reagent cost of a comparable commercially available flow cytometric assay in Africa is $5.04$ (£2.52, €3.74). As we were able to reduce costs of reagents to $0.44$ (£0.22, €0.33) per assay, there is the potential for 91% cost savings. This would increase to 98% if only CD4 percentage is required but would decrease if the costs of competing tests are reduced.

Cost reduction was not achieved at the expense of accuracy. Over the CD4 count range of 0-400 $\times 10^9$ l$^{-1}$, our assay showed minimal bias and excellent agreement compared with established CD4 counting methods (TruCount and FACSCount). Determination of CD4 percentage by Blantyre count and TruCount methods showed excellent agreement over the full range of CD4 percentages. The good performance of Blantyre count in the NEQAS immunophenotyping scheme further shows the accuracy of this method.

As well as reducing the assay price, the modifications in our assay have simplified CD4 counting with flow cytometry. Use of a primary CD4 gating strategy avoids extra sub-gating steps involving the CD3 or CD45 cell populations as performed by other established methods, including TruCount/Multitest and Panleucogating technologies. It has proved straightforward to train technicians to gate the CD4 T cells (R1, counting beads (R2), and total lymphocyte populations (R3) using CD4/side scatter and CD45/side scatter dot plots (fig 1).

**Strengths and weakness of study**

Our study validates the use of a simplified, affordable, and accurate method of CD4 counting with flow cytometry. Unlike many previous studies of affordable flow cytometry, we carried out this work in a country where affordability is of chief importance. We looked at both absolute and percentage CD4, which have previously been neglected. The limits of agreement are similar to those of previous comparison studies of flow cytometry and narrower than studies using other methods, which are inherently less accurate. By miniaturising the present assay, we managed to reduce reagent costs further compared with previous studies.

Even with the simplifications introduced, however, CD4 counting with flow cytometry requires a level of technical skill not always present in resource poor settings, a reliable power supply, and a cold chain for reagent supplies. A flow cytometer represents a large capital outlay, which is not always feasible, although donor funding is sometimes available to help provide such instruments.

Users of FACSCount and other methods that provide only the absolute CD4 count have needed to use total lymphocyte counts (usually from haematological analysers) to obtain the CD4 percentage. The poor agreement between CD4 percentage obtained by combined FACSCount plus haematological analysis when compared with CD4 percentage produced by either Blantyre count or TruCount (table 2, fig 2) shows the inaccuracy of this laborious “reversed dual platform” approach. It is well recognised that flow cytometers and haematological analysers can produce significantly different total lymphocyte counts for the same blood sample.

**Table 3 | Comparison of clinical staging with absolute CD4 count with Blantyre count for new patients seen at antiretroviral clinic**

<table>
<thead>
<tr>
<th>Clinical stage</th>
<th>No (% of patients)</th>
<th>Median (range) CD4 $\times 10^9$ l$^{-1}$</th>
<th>No (%) with CD4 $&gt;350 \times 10^9$ l$^{-1}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>77 (30)</td>
<td>286 (20-1020)</td>
<td>25 (32)</td>
</tr>
<tr>
<td>II</td>
<td>116 (46)</td>
<td>249 (4-1261)</td>
<td>48 (42)</td>
</tr>
<tr>
<td>III</td>
<td>51 (20)</td>
<td>149 (11-826)</td>
<td>29 (57)</td>
</tr>
<tr>
<td>IV</td>
<td>9 (4)</td>
<td>110 (16-552)</td>
<td>7 (78)</td>
</tr>
<tr>
<td>All</td>
<td>253</td>
<td>239 (4.1-1261)</td>
<td>110 (43)</td>
</tr>
</tbody>
</table>

Note: Comparison of clinical staging with absolute CD4 count with Blantyre count for new patients seen at antiretroviral clinic.
The excellent agreement between Blantyre count and TruCount assays indicates that use of CD3 antibody by TruCount is redundant in CD4 counting with flow cytometry. This means that Blantyre count technology could be operated on less complex instruments than the FACSCalibur, deploying only one laser and three photomultiplier tubes to detect side scattered light and fluorescence emitted from FITC and PE fluorochromes. Such an instrument could be manufactured at lower cost compared with the FACSCalibur and would be simpler and less expensive to maintain. Even on five day old blood, our gating strategy enabled both CD4 T cells and lymphocytes to be easily discriminated from monocytes, thereby maintaining good repeatability with little variability from day one counts.

Blantyre count could make the greatest impact on the care of children under 5 with HIV. Appropriate determination of CD4 percentage has often been neglected by investigators seeking to produce affordable CD4 counting.68 Determination of CD4 percentage alone by the Blantyre count (percentage) variant is not only much cheaper than determining absolute CD4 counts but also technically easier, as accurate volumetric pipetting and counting beads are not required. CD4 percentages were also more stable than absolute counts over five days in the same sample.

The determination of CD4 counts with Blantyre count in the antiretroviral therapy clinic confirms that use of WHO clinical staging criteria alone for deciding who should start antiretroviral therapy is suboptimal. About a third of patients with clinical stage I or II disease who would not be eligible for antiretroviral therapy on clinical grounds were severely immunosuppressed with a CD4 count of <200 × 10^9/l. Conversely, two thirds of patients with stage III and IV disease who were eligible to start antiretroviral therapy had CD4 counts >200 × 10^9/l and a fifth had counts >350 × 10^9/l. Clinical staging alone is missing many patients who urgently need to start antiretroviral therapy, while some stage III and IV patients are started on antiretroviral therapy when treatment could potentially be postponed.

What would it cost?

Consideration of the economic feasibility of using the Blantyre count in Malawi has to include the capital cost of the flow cytometer (about $100 000), the annual service contract (about $10 000), and the salary of a laboratory technician (typical monthly salary $500) as well as reagent prices. The contribution of these non-reagent costs to the total cost per assay is inversely proportional to assay throughput. With the cost of such an instrument spread over 10 years, CD4 counting with flow cytometry would not be viable if only 200 samples were run on an instrument each month, as “non-reagent costs” per sample would be $10.83. If, however, 200 samples are run on a flow cytometer each day, which is well within the capacity of the instrument (over 250 days this would be 50 000 samples a year), non-reagent costs are $0.52 per sample, giving a total assay cost of $0.96. Therefore, use of the Blantyre count method would be most cost effective with a limited number of flow cytometers operating at high sample throughput in regional centres and a coordinated system for transporting samples to these centres from peripheral clinics.

We have described an affordable accurate method of CD4 counting that has the potential to improve clinical decision making in the treatment of patients with HIV and service the whole of a country the size of Malawi using a limited number of instruments in regional centres. This arrangement could be facilitated by the use of blood stabilising agents such as Transfix, permitting delays in sending samples to regional centres.29 It remains to be seen whether such a service could be successfully implemented in such a resource poor setting.

We thank Emily Lifa for blood sampling in the antiretroviral therapy clinic at Queen Elizabeth Central Hospital and all staff at the antiretroviral therapy clinic for their assistance with this study.

Contributors: CAMacL was responsible for the study conception, coordinated the study, drafted the initial manuscript, and is guarantor. CAMacL, MKPL, MEM, MTD, JcGo, MJM, and EEE contributed to the study design. MKPL and CAMacL optimised the Blantyre count method. CAMacL, MKPL, FS, and JB did flow cytometric assays. CAMacL, SAW, and MKPL analysed the data. All authors contributed to the writing of the manuscript and approved the final version.

Funding: CAMacL holds a training fellowship in clinical tropical medicine from the Wellcome Trust (No. 067902/2/02/2). MKPL received a travel award from the British Society for Immunology. MEM holds a programme grant from the Wellcome Trust (No. 074242/2/04/Z).

Competing interests: None declared.

Ethical approval: College of Medicine research and ethics committee.

Peer review and provenance: Non-commissioned, externally peer reviewed.


